Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients
| Autor: | Swen Hesse, Julia Luthardt, Donald Lobsien, C Schinke, Karl-Titus Hoffmann, S Haars, Osama Sabri, Muriel Stoppe, F. Then Bergh, Elisa Schmidt, Georg-Alexander Becker, Michael Rullmann |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_treatment lcsh:Medicine Noradrenaline Transporter Article Multiple sclerosis Disability Evaluation Norepinephrine Reboxetine Young Adult Multiple Sclerosis Relapsing-Remitting Medicine Humans Carbon Radioisotopes lcsh:Science Transporters in the nervous system Fatigue Psychiatric Status Rating Scales Norepinephrine Plasma Membrane Transport Proteins Molecular medicine business.industry Depression lcsh:R Brain Immunotherapy Middle Aged medicine.disease Magnetic Resonance Imaging Positron-Emission Tomography Immunology lcsh:Q Female business |
| Zdroj: | Scientific Reports Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020) |
| ISSN: | 2045-2322 |
| Popis: | The neurotransmitter noradrenaline (NA) mediates arousal, attention and mood, and exerts anti-inflammatory and neuroprotective effects. Alterations of monoamine signalling were reported in multiple sclerosis (MS) and psychiatric illness and may account for the high prevalence of comorbid depression and fatigue in MS patients. We assessed central noradrenaline transporter (NAT) availability using positron emission tomography (PET) and the NAT selective radiotracer S,S-[11C]O-methylreboxetine in immunotherapy-naïve patients with relapsing–remitting MS (RRMS; n = 11) compared to healthy controls (HC; n = 12), and its association to lesion load, time since manifestation, the expanded disability status scale (EDSS), the fatigue scale Würzburger Erschöpfungsinventar bei MS (WEIMuS) and Beck Depression Inventory (BDI). We found NAT availability to be increased in the thalamus, amygdala, putamen and pons/midbrain of MS patients. No relation to clinical or psychometric variables was found. These first data indicate higher NAT availability in subcortical brain regions of immunotherapy-naïve RRMS patients. If these changes of noradrenergic neurotransmission predispose to psychiatric symptoms or associate with disease activity needs to be investigated in longitudinal studies or a larger sample which allows subgroup analyses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|